Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced
Plus Therapeutics Announces Validation & Clinical Implementation Of CSF-01 Leptomeningeal Cancer Cell Diagnostic
Plus' CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeningesCSF-01 testing is used as an expl
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Plus Therapeutics Faces Nasdaq Delisting Over Equity Shortfall
Plus Therapeutics CEO's Insightful Presentation Now Available
Express News | Plus Therapeutics Has Completed Dosing In Cohort 5 Of ReSPECT-LM Phase 1 Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases From Solid Tumors; Company Expects Moving Into Cohort 6 In Q2 2024 Following Standard Safety Review
Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials
Plus Therapeutics Is Worried About This – Should You Be Worried Too?
Q4 2023 Plus Therapeutics Inc Earnings Call
Earnings Call Summary | Plus Therapeutics(PSTV.US) Q4 2023 Earnings Conference
The following is a summary of the Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript:Financial Performance:Plus Therapeutics reported a decrease in cash reserves to $8.6 million by the en
Recap: Plus Therapeutics Q4 Earnings
Plus Therapeutics (NASDAQ:PSTV) reported its Q4 earnings results on Tuesday, March 5, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsPlus Therapeutics beat estimate
Plus Therapeutics Q4 EPS $(0.70) Beats $(1.07) Estimate, Sales $1.31M Beat $1.06M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1.07) by 34.58 percent. This is a 70.83 percent increase over losses of $(
Plus Therapeutics FY23 Loss $13.3M >PSTV
Plus Therapeutics FY23 Loss $13.3M >PSTV
Plus Therapeutics FY23 Loss/Shr $4.24 >PSTV
Plus Therapeutics FY23 Loss/Shr $4.24 >PSTV
Plus Therapeutics GAAP EPS of -$4.24 Misses by $3.07
Plus Therapeutics: Financial Forecast for Sufficient Runway to Fund Ops Into 2H 2025 >PSTV
Plus Therapeutics: Financial Forecast for Sufficient Runway to Fund Ops Into 2H 2025 >PSTV
Press Release: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Began enrollment of the 5(th) of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. • Target (NYSE:TGT) is estimated to report quarterly earnings
Notable Earnings After Tuesday's Close
No Data